GEP20104875B - Pyrimidine derivatives for the treatment of abnormal cell growth - Google Patents

Pyrimidine derivatives for the treatment of abnormal cell growth

Info

Publication number
GEP20104875B
GEP20104875B GEAP20059703A GEAP2005009703A GEP20104875B GE P20104875 B GEP20104875 B GE P20104875B GE AP20059703 A GEAP20059703 A GE AP20059703A GE AP2005009703 A GEAP2005009703 A GE AP2005009703A GE P20104875 B GEP20104875 B GE P20104875B
Authority
GE
Georgia
Prior art keywords
treatment
cell growth
abnormal cell
pyrimidine derivatives
prodrug
Prior art date
Application number
GEAP20059703A
Other languages
English (en)
Inventor
John Charles Kath
Michael Joseph Luzzio
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34966230&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GEP20104875(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of GEP20104875B publication Critical patent/GEP20104875B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
GEAP20059703A 2004-05-14 2005-05-02 Pyrimidine derivatives for the treatment of abnormal cell growth GEP20104875B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57131204P 2004-05-14 2004-05-14

Publications (1)

Publication Number Publication Date
GEP20104875B true GEP20104875B (en) 2010-01-11

Family

ID=34966230

Family Applications (1)

Application Number Title Priority Date Filing Date
GEAP20059703A GEP20104875B (en) 2004-05-14 2005-05-02 Pyrimidine derivatives for the treatment of abnormal cell growth

Country Status (27)

Country Link
EP (1) EP1751143A1 (zh)
JP (1) JP4099212B2 (zh)
KR (1) KR100886990B1 (zh)
CN (2) CN102127058A (zh)
AP (1) AP2241A (zh)
AR (1) AR049097A1 (zh)
AU (2) AU2005243397A1 (zh)
BR (1) BRPI0511138A (zh)
CA (1) CA2566707A1 (zh)
CR (1) CR8749A (zh)
EA (1) EA200601796A1 (zh)
EC (1) ECSP066997A (zh)
GE (1) GEP20104875B (zh)
GT (1) GT200500113A (zh)
IL (1) IL178828A0 (zh)
MA (1) MA28583B1 (zh)
MX (1) MXPA06011890A (zh)
NL (2) NL1029045C2 (zh)
NO (1) NO20064576L (zh)
NZ (1) NZ550448A (zh)
PA (1) PA8632601A1 (zh)
PE (1) PE20060240A1 (zh)
TN (1) TNSN06370A1 (zh)
TW (1) TWI303635B (zh)
UY (1) UY28894A1 (zh)
WO (1) WO2005111023A1 (zh)
ZA (1) ZA200608394B (zh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1763514A2 (en) * 2004-05-18 2007-03-21 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
US20070032514A1 (en) * 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
AU2006327871A1 (en) * 2005-12-21 2007-06-28 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
CA2684447C (en) * 2007-04-18 2012-01-24 Pfizer Products Inc. Sulfonyl amide derivatives for the treatment of abnormal cell growth
KR20100049068A (ko) * 2007-07-17 2010-05-11 리겔 파마슈티칼스, 인크. Pkc 억제제로서의 시클릭 아민 치환된 피리미딘디아민
CA2707653A1 (en) * 2007-12-03 2009-06-11 Boehringer Ingelheim International Gmbh Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation
MX2010012703A (es) * 2008-05-21 2010-12-21 Ariad Pharma Inc Derivados fosforosos como inhibidores de cinasa.
US8410126B2 (en) * 2009-05-29 2013-04-02 Boehringer Ingelheim International Gmbh Pyrimidine inhibitors of PKTK2
EP2464633A1 (en) 2009-08-14 2012-06-20 Boehringer Ingelheim International GmbH Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
WO2014174745A1 (ja) * 2013-04-26 2014-10-30 国立大学法人京都大学 Eg5阻害剤
CN109608444B (zh) * 2018-11-27 2022-02-11 中国药科大学 含异吲哚啉酮的erk抑制剂及其制备方法与用途
CN111732548B (zh) * 2020-06-11 2022-06-17 浙江大学 N2-氨甲酰芳环-2-氨基嘧啶类衍生物及其医药用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721437D0 (en) * 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
AR042586A1 (es) 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
WO2003030909A1 (en) * 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
ATE458731T1 (de) * 2002-12-20 2010-03-15 Pfizer Prod Inc Pyrimidin-derivate zur behandlung von anormalem zellwachstum
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth

Also Published As

Publication number Publication date
NZ550448A (en) 2010-11-26
CR8749A (es) 2006-12-05
EP1751143A1 (en) 2007-02-14
BRPI0511138A (pt) 2007-11-27
CN102127058A (zh) 2011-07-20
AU2009238255A1 (en) 2009-12-03
JP2007537234A (ja) 2007-12-20
PE20060240A1 (es) 2006-04-01
AR049097A1 (es) 2006-06-28
NL1029045A1 (nl) 2005-11-15
IL178828A0 (en) 2007-03-08
ZA200608394B (en) 2008-05-28
ECSP066997A (es) 2007-02-28
NO20064576L (no) 2006-11-07
MA28583B1 (fr) 2007-05-02
TW200539871A (en) 2005-12-16
CN1953974A (zh) 2007-04-25
KR20070012477A (ko) 2007-01-25
PA8632601A1 (es) 2006-06-02
NL1031845A1 (nl) 2006-07-31
TNSN06370A1 (fr) 2008-02-22
CA2566707A1 (en) 2005-11-24
KR100886990B1 (ko) 2009-03-04
MXPA06011890A (es) 2006-12-14
UY28894A1 (es) 2005-12-30
AU2005243397A1 (en) 2005-11-24
AP2006003790A0 (en) 2006-10-31
GT200500113A (es) 2006-01-10
EA200601796A1 (ru) 2007-04-27
WO2005111023A1 (en) 2005-11-24
AP2241A (en) 2011-06-01
TWI303635B (en) 2008-12-01
JP4099212B2 (ja) 2008-06-11
NL1029045C2 (nl) 2006-06-02
NL1031845C2 (nl) 2006-11-23

Similar Documents

Publication Publication Date Title
GEP20104875B (en) Pyrimidine derivatives for the treatment of abnormal cell growth
GEP20084357B (en) Pyrimidine derivatives for the treatment of abnormal cell growth
GEP20094605B (en) Pyrazole derivatives, compositions containing such compounds and methods of use thereof
GEP20104895B (en) Preparation of pregabalin and related compounds
GEP20125456B (en) Azetidines as mek inhibitors for the treatment of proliferative diseases
TW200642689A (en) Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient
MY139302A (en) Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof
WO2006084017A3 (en) Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
MXPA06013164A (es) Derivados de pirimidina para el tratamiento de crecimiento de celulas anormal.
TW200732303A (en) Novel fused pyrrole derivatives
TW200740758A (en) Benzoquinazoline derivatives
GEP20156282B (en) Compounds and compositions as protein kinase inhibitors
SE0202463D0 (sv) Novel compounds
ATE450533T1 (de) Carboxamidderivate
GEP20104964B (en) 3-aminocarbazole compounds, pharmaceutical composition containing the same and method for the preparation thereof
MX2007013624A (es) Inhibidores de proteina cinasa.
MX2007003546A (es) Derivados de indozolona como inhibidores de 11-beta- hidroxiesteroide-deshidrogenasa.
MXPA05012415A (es) Inhibidores de glutamina fructosa-3-fosfato amidotransferasa (gfat).
TW200639156A (en) New compounds
MY137156A (en) Dual nk1/nk3 derivatives
MX2007004302A (es) Inhibidores de pi3 cinasa gamma para el tratamiento de anemia.
TW200626145A (en) Heterocyclic compounds and thrombopoietin receptor activators
MY140630A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
AU2003250471A8 (en) Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
HK1114516A1 (en) Substituted sulfoxide compounds, methods for preparing the same and use thereof